Lin C, Radwanski E, Affrime M, Cayen M N
Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.
Antimicrob Agents Chemother. 1995 Feb;39(2):356-8. doi: 10.1128/AAC.39.2.356.
The pharmacokinetics of ceftibuten, a new cephalosporin antibiotic, and its conversion product, ceftibutentrans, were studied in healthy male volunteers following daily oral administration of a 400-mg capsule for 7 days. Mean concentrations of ceftibuten in plasma obtained on day 5 were similar to those obtained on day 7. Analysis of variance indicated that the concentrations in plasma on days 5 and 7 were at steady state. The mean accumulation factor was 1.14 for day 5 and 1.13 for day 7. The half-life (2.4 h) was independent of the duration of drug administration, and the mean maximum concentration of drug in plasma was 18 to 19 micrograms/ml. Urinary excretion was the major elimination route for ceftibuten, by which 57 to 59% of the drug was excreted unchanged over a 24-h period. The amounts of ceftibuten-trans in plasma and urine were low.
在健康男性志愿者中,连续7天每日口服一粒400毫克胶囊后,研究了新型头孢菌素抗生素头孢布烯及其转化产物头孢布烯反式异构体的药代动力学。第5天获得的血浆中头孢布烯的平均浓度与第7天获得的相似。方差分析表明,第5天和第7天血浆中的浓度处于稳态。第5天的平均蓄积因子为1.14,第7天为1.13。半衰期(2.4小时)与给药持续时间无关,血浆中药物的平均最大浓度为18至19微克/毫升。尿液排泄是头孢布烯的主要消除途径,在24小时内,57%至59%的药物以原形排泄。血浆和尿液中头孢布烯反式异构体的量很低。